# US 2023/0096220 A1 · Novel subtituted sulfonylurea and sulfoximineurea derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0096220 A1
- Document ID: US20230096220A1
- Status: Published application
- Kind: A1
- Application number: 17/800,261
- Filed: 2021-02-26
- Published: 2023-03-30
- Earliest claimed: 2020-02-28
- Assignees: Zydus Lifesciences Limited
- Applicants: Zydus Lifesciences Limited
- Inventors: Rajiv SHARMA; Sameer AGARWAL
- Web page: https://patentgrep.com/patent/US20230096220A1

## CPC

- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 38/20: Interleukins [IL]
- A61K 38/21: Interferons {[IFN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 311/55: having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
- C07C 381/10: Compounds containing sulfur atoms doubly-bound to nitrogen atoms
- C07D 211/58: attached in position 4
- C07D 295/084: with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 295/088: to an acyclic saturated chain
- C07D 295/13: to an acyclic saturated chain
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07D 335/02: not condensed with other rings
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2603/10: containing five-membered rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1β activity is implicated.

## Claims

### Claim 1

Compound having the structure of general formula (I)
their tautomeric forms, their stereoisomers, their enantiomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them wherein
Each of R1 and R2 at each occurrence independently represents hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C1-C6)alkylSO2(C1-C6)alkyl, (C1-C6)alkylN(C1-C6)alkyl, (C1-C6)alkylN(C3-C7)cycloalkyl, aryl, heteroaryl, heterocyclyl, benzyl, tert-butyloxycarbonyl, thiol, mercaptoalkyl, SO2(C1-C6)alkyl, SO2(C3-C7)cycloalkyl, SO2-aryl, SO2-heterocyclyl, (C1-C6)thioalkyl, (C1-C6)thioalkoxy, (C1-C6)alkylSO2NH2, —CONH2, —CO (C1-C6)alkyl, —CO(C1-C6)haloalkyl, CO(O)(C1-C6)alkyl, —CO-aryl, —CO-heteroaryl, —CO-heterocyclyl, 4- to 7-membered heterocyclic ring, 7- to 14-membered bicyclic heterocyclic ring system, bridged or spiro ring system having optionally one or more than one heteroatoms;
Alternatively R1, R2 and N together may form a saturated or partially saturated 3 to 8 membered heterocyclic ring system, 7- to 14-membered bicyclic heterocyclic ring system, bridged or spiro ring system having optionally one or more than one heteroatoms;
Each of R3 and R4 at each occurrence represents hydrogen, halogen, haloalkyl, cyano, nitro, amide, sulphonamide, acyl, hydroxyl, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, SO2(C1-C6)alkyl, thiol, mercapto alkyl benzyl, aryl, heteroaryl, heterocyclyl;
Alternatively R3 and R4 may forms a bond;
X is O, N—R6; wherein R6 at each occurrence independently represents hydrogen, hydroxyl, halogen, nitro, cyano, haloalkyl, optionally substituted groups selected from (C1-C10)alkyl, (C1-C10)alkoxy, (C3-C10)cycloalkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, SO2(C1-C6)alkyl, thiol, thioalkyl, thio-alkoxy, SO2(C1-C6)alkyl, SO(C1-C6)alkyl, benzyl, aryl, heteroaryl, heterocyclyl;
n, is independently selected from integer 0-3;
R5 at each occurrence independently represents hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)alkoxy, (C2-C6)alkenyl, (C3-C7)cycloalkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy, SO2(C1-C6)alkyl, SO(C1-C6)alkyl, bridged or spiro ring system having optionally one or more than one heteroatoms;
‘A’ is selected from the following ring system
wherein X, Y, Z at each occurrence independently represents C, N, S, SO2, and O, which may be optionally substituted;
Each of R7, R8, R9, R10, R11 and R12 at each occurrence are independently selected from hydrogen, halogen, cyano, amide, sulphonamide, acyl, hydroxyl, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy, benzyl, aryl, heteroaryl, heterocyclyl; Alternatively each of R8 and R9, R9 and R10, R10 and R11 and R11 and R12 wherever possible, together may form a 4 to 7 membered saturated or partially saturated ring containing from 0-2 additional heteroatoms selected from the group consisting of N, O, and S(O)p; p=1-2.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein R3 and R4 at each occurrence is independently selected from hydrogen, halogen, optionally substituted group selected from (C1-C6)alkyl.

### Claim 3 (depends on 1)

The compound as claimed in claim 1, wherein R5 at each occurrence is independently selected from hydrogen, halogen, optionally substituted groups selected from (C1-C6)alkyl.

### Claim 4 (depends on 1)

The compound as claimed in claim 1, wherein R6 at each occurrence is independently selected from optionally substituted groups selected from hydrogen, cyano.

### Claim 5 (depends on 1)

The compound as claimed in claim 1, wherein each of R7, R8, R9, R10, R11 and R12 at each occurrence is independently selected from hydrogen, halogen optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl.

### Claim 6 (depends on 1)

The compound as claimed in claim 1, wherein when any of the R groups are substituted, the substitutions are selected from hydrogen, hydroxy, cyano, halo, haloalkyl, haloalkyloxy, alkylthio, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, C1—(C1-C6)alkoxy, aryl, heterocyclyl, heteroaryl, —COR11, —CSR11, C(O)OR11, C(O)—R11, —C(O)—NR11R12, —C(S)—NR11R12, —SO2R11 group, wherein each of, R11 and R12 is independently selected from hydrogen, optionally substituted group selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C7)cycloalkyl, aryl, heteroaryl, heterocyclyl groups.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 selected from the group comprising of:
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(isopropylamino)prop-1-ene-1-sulfonamide;
(E)-3-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methyl(propyl)amino)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(propylamino)prop-1-ene-1-sulfonamide;
(E)-3-((cyclopropylmethyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-3-((cyclopropylmethyl)(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-3-(ethyl(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(N-methylmethylsulfonamido)prop-1-ene-1-sulfonamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)-N-methylcyclopropanesulfonamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)-N-methylcyclohexanesulfonamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)cyclohexanesulfonamide;
(E)-3-((cyclohexylmethyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-3-((cyclohexylmethyl)(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)-N-methylcyclohexanecarboxamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)-N-methylacetamide;
(E)-N-(3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)allyl)-N-methylcyclopropanecarboxamide;
(E)-N-((2,6-diisopropylphenyl)carbamoyl)-3-(dimethylamino)prop-1-ene-1-sulfonamide;
(E)-N-((2,6-diisopropyl-4-methylphenyl)carbamoyl)-3-(dimethylamino)prop-1-ene-1-sulfonamide;
(E)-3-(dimethylamino)-N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methyl(phenyl)amino)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(phenylamino)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(thiazol-2-ylamino)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methyl(thiazol-2-yl)amino)prop-1-ene-1-sulfonamide;
(E)-N′-cyano-3-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-3-(ethyl(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-3-((cyclopropylmethyl)(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-3-((cyclopropylmethyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-3-(dimethylamino)-N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-3-((cyclopropylmethyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-3-((cyclopropylmethyl)(methyl)amino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-3-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-3-(dimethylamino)-N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)prop-1-ene-1-sulfonimidamide;
(E)-3-(dimethylamino)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methylprop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(methyl(oxetan-3-yl)amino)prop-1-ene-1-sulfonimidamide;
(E)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(oxetan-3-ylamino)prop-1-ene-1-sulfonimidamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(oxetan-3-ylamino)prop-1-ene-1-sulfonimidamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(oxetan-3-ylamino)prop-1-ene-1-sulfonamide
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(5-(methylsulfonyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide;
(E)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(5-(methylsulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-1-ene-1-sulfonamide
or pharmaceutically acceptable salts of any of the compounds above.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1 and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 9 (depends on 1)

A method of treating diseases medicated by the NLRP3 modulators as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) are implicated which comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) as claimed in claim 1 or its suitable pharmaceutical composition.

### Claim 10 (depends on 1)

The use of compounds of formula (I) or its pharmaceutical compositions as claimed in claim 1 suitable for treatment of diseases wherein the NLRP3 modulator has a pathophysiological function.

### Claim 11 (depends on 8)

The pharmaceutical composition as claimed in claims 8 in combination with one or more suitable pharmaceutically active agents selected from Inhibitors of interleukin-1β; immune-suppressants; metabolic disorders drugs, glucocorticoids, non-steroidal anti-inflammatory drugs, COX-2 specific inhibitors, anti-inflammatory drugs, TNF-α binding proteins, interferon-13, interferon, interleukin-2, antihistamines, beta-agonist, STK inhibitors, anticolinergics, anti-cancer agents or their suitable pharmaceutically acceptable salts, Non-Alcoholic Steato-Hepatitis (NASH) and fibrosis drugs, anticancer drugs, antibiotics, hormones, aromatase inhibitors, inhibitors of mitogen-activated protein kinase signaling, Syk inhibitors, mTOR inhibitors, SCR/ASL antagonists, Arenaviridae virus infections, particularly Lassa virus and Junin virus infections, antibiotic and/or antifungal prophylaxis, fever and pain medication, antiemetic and/or antidiarrheal agents, vitamin and mineral supplements, anti-inflammatory agents, anti-inflammatory and immunosuppressant agents, pain medications, and medications for other common diseases in the patient population, anti-malarial agents and cephalosporin antibiotics.
